Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Posted on by Pencis

Assoc Prof Dr. Haruto Nishida | Breast Cancer Immunity | Best Researcher Award

Faculty of Medicine, Oita University | Japan

Author Profile

Scopus

🧬 Dr. Haruto Nishida, M.D., Ph.D. – Associate Professor of Diagnostic Pathology

Haruto Nishida, M.D., Ph.D., is an Associate Professor at the Department of Diagnostic Pathology at Oita University Hospital, Japan, where he has served in this role since April 2021. Dr. Nishida has a profound expertise in pathology, with a particular focus on diagnostic pathology, cytology, and molecular pathology.

🎓 Education and Early Career

Dr. Nishida earned his Medical Degree from the Faculty of Medicine at Oita University in 2009. He furthered his academic journey by obtaining a Ph.D. from the same institution in 2015, specializing in pathology. His post-graduate training includes a residency in General Medicine at Oita Medical Hospital and a fellowship in Diagnostic Pathology at Oita University.

🩺 Professional Experience

Dr. Nishida’s career at Oita University has been marked by progressive roles. Starting as an Assistant Professor in 2012, he was promoted to Lecturer in 2019 and then to Associate Professor in 2020. He continued in this role when he transitioned to Oita University Hospital in 2021, where he currently leads efforts in diagnostic pathology.

🏅 Board Certifications and Licensure

Dr. Nishida holds multiple prestigious board certifications, including the Japanese Board Certification in Pathology, Autopsy, Cytology, and Molecular Pathology. He earned his National Board of Medicine license in 2009, showcasing his dedication to the field.

🌍 Professional Affiliations

Dr. Nishida is an active member of several professional organizations, both in Japan and internationally. He is involved with the Japanese Society of Pathology, Japanese Society of Clinical Cytology, Japan Dermatopathology Society, and the Bone and Soft Tissue Tumor Club of Japan. Additionally, he is a member of the United States and Canadian Academy of Pathology (USCAP) and the International Academy of Cytology.

Dr. Nishida’s contributions to the field of pathology, combined with his ongoing research and teaching, make him a distinguished figure in diagnostic pathology.

🚀 Conclusion

In summary, Dr. Haruto Nishida is a highly accomplished pathologist whose extensive expertise and dedication to diagnostic pathology have significantly contributed to the field. His career, marked by a progression of academic and clinical roles at Oita University, is underpinned by his strong educational background and numerous board certifications. As an active member of both national and international professional organizations, Dr. Nishida continues to impact the field through his research, teaching, and clinical work. His ongoing commitment to excellence in pathology makes him a respected leader in the medical community.

 

📊🔬NOTABLE PUBLICATION:

 

  • SOX10-Internal Tandem Duplications and PLAG1 or HMGA2 Fusions Segregate Eccrine-Type and Apocrine-Type Cutaneous Mixed Tumors
    Authors: Macagno, N., Kervarrec, T., Thanguturi, S., De la Fouchardière, A., Battistella, M.
    Journal: Modern Pathology
    Year: 2024

 

  • Recurrent Cardiac Tamponade Following Coronavirus Disease 2019 mRNA Vaccination: A Case Report
    Authors: Kaimori, R., Nishida, H., Yahiro, T., Iwami, T., Daa, T.
  • Journal: Cardiovascular Pathology
    Year: 2024

 

  • Lipid Droplet Detection in Histopathological Images Using Reinforcement Learning
    Authors: Harada, Y., Nishida, H., Matsuura, K.
    Journal: Biotechnology and Biotechnological Equipment
    Year: 2024

 

  • Right Atrial Cardiac Myxoma with Malignant Transformation to Undifferentiated Sarcoma: A Case Report
    Authors: Kaimori, R., Nishida, H., Oyama, Y., Kawamura, K., Daa, T.
    Journal: Cardiovascular Pathology
    Year: 2024

 

  • The Relationship Between Tumor Immunity and the cGAS–STING Pathway in Breast Cancer: An Immunohistochemical Study
    Authors: Nishida, H., Ohara, N., Kato, A., Kawamura, K., Daa, T.
    Journal: Experimental and Molecular Pathology
    Year: 2024

Prof. Wenhao Ouyang – Tumor Immunology – Best Researcher Award

Posted on by Pencis

Prof. Wenhao Ouyang - Tumor Immunology - Best Researcher Award

Sun Yat-Sen Memorial Hospital - China

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS:

Wenhao Ouyang commenced his academic journey at Sun Yat-sen University, delving into the field of Medical Oncology. His early academic pursuits laid the foundation for a career marked by dedication to advancing cancer research and treatment.

PROFESSIONAL ENDEAVORS:

As a Physician and Ph.D. Candidate at Sun Yat-sen Memorial Hospital, Wenhao Ouyang's professional endeavors center around tumor big data, artificial intelligence research, tumor immunology, and immunotherapy research. His dual role as both a clinician and researcher highlights his commitment to bridging the gap between clinical practice and cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Wenhao Ouyang has made substantial contributions to the field through his research, focusing on tumor big data, artificial intelligence, and tumor immunology. His published articles in esteemed journals showcase the depth and breadth of his research, with a focus on prognostic factors, immunotherapy response, and the tumor microenvironment.

IMPACT AND INFLUENCE:

Ouyang's impact is evident through his published articles, each addressing critical aspects of cancer research. His work, such as developing prognostic risk scores and identifying immune-inflammation signatures, reflects his influence on shaping the understanding of cancer prognosis and treatment response.

ACADEMIC CITES:

Being a reviewer for Frontiers in Immunology underscores Wenhao Ouyang's standing in the academic community. Reviewing articles in this reputable journal demonstrates his expertise and recognition within the field, contributing to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS:

Wenhao Ouyang's legacy is unfolding through a substantial body of work that has already left a mark on cancer research. His role as a major participant in the selection of articles for the 2023 ESMO Asia poster highlights his commitment to sharing knowledge and advancing the field on a global scale.

HIGHLIGHT OF FUTURE CONTRIBUTIONS:

Looking forward, Ouyang's involvement in groundbreaking projects, such as multimodal data fusion for improved risk stratification of breast cancer, signals a trajectory of continued impact. His role in precision neoadjuvant chemotherapy and distinguishing tumor immunotyping heterogeneity positions him as a key figure in shaping the future of cancer research and treatment.

NOTABLE PUBLICATION

Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. 2023 (1)

Machine learning radiomics of magnetic resonance imaging predicts recurrence-free survival after surgery and correlation of LncRNAs in patients with breast cancer: a multicenter cohort study. 2023 (1)

Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer. 2023

A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma. 2023

Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma. 2022 (2)

A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. 2022 (19)

 

 

 

Assoc Prof Dr. Mario I. Vega – Tumor Immunology – Best Researcher Award

Posted on by Pencis

 

Assoc Prof Dr. Mario I. Vega - Tumor Immunology - Best Researcher Award

University of California Los Angeles - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS:

Mario I. Vega initiated his academic journey at the Universidad Autónoma Metropolitana Campus Xochimilco, Mexico City, serving as a Research Technical Assistant in the Department of Leptospirosis Human Research from 1991 to 1992. He continued his research roles at the Hospital Infantil de Mexico "Federico Gomez" and the Instituto Mexicano del Seguro Social (IMSS) with a focus on immunology and infectious diseases.

PROFESSIONAL ENDEAVORS:

Mario I. Vega's professional trajectory includes positions at prestigious institutions, such as UCLA AIDS Institute and IMSS, where he advanced from Assistant Researcher to Professor in the field of tumor immunology and infectious diseases. Notably, he has been associated with UCLA Medical Center, Jonsson Comprehensive Cancer Center, contributing as Staff Associate Researcher in the Clinical Nutrition Division.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY:

Dr. Vega's research contributions span diverse areas, from rituximab inhibition of p38 MAPK activity in B NHL to extensive work in immunology, cancer, and infectious diseases. His research expertise includes molecular biology, DNA replication, PCR, and immunotherapy. Serving on various review committees and editorial boards, he has actively contributed to scientific evaluations and publications.

IMPACT AND INFLUENCE:

Dr. Mario I. Vega's impact is evident through numerous honors and awards, such as the American Society of Hematology (ASH) Travel Award in 2004 and consecutive Fogarty fellowships at UCLA from 2004 to 2013. His recognition extends to national and international awards in pediatric research, biomedical research, and contributions to scientific journals.

ACADEMIC CITES:

Dr. Vega has left a mark on academia with memberships in esteemed organizations like ASH, AACR, and AAI. His participation in teaching activities, including courses on molecular biology, immunology, and cancer, demonstrates his commitment to knowledge dissemination.

LEGACY AND FUTURE CONTRIBUTIONS:

This overview highlights Dr. Mario I. Vega's academic and professional journey, his substantial contributions to medical research, and the potential impact of his continued work on the fields of immunology and oncology.

Notable Publications

Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma.2019 

Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.2022

Roles and Regulation of BCL-xL in Hematological Malignancies.2022